US Theranostics Market – FDA Approvals Expanding Clinical Applications
Market Overview
FDA approvals are expanding clinical applications in the US theranostics market, enabling new diagnostic and therapeutic options for cancer patients. Recent approvals of radiopharmaceuticals including Pluvicto for prostate cancer and Lutathera for neuroendocrine tumors have established theranostics as a standard-of-care approach in precision oncology. The market is projected to grow through 2030, fueled by continued regulatory support and clinical adoption.
The US Theranostics Market benefits from a streamlined FDA approval pathway for companion diagnostics and therapeutic radiopharmaceuticals. Ongoing clinical trials are investigating new agents for breast, lung, and colorectal cancers. Expanded approvals are expected to drive market growth significantly.
Current Market Landscape
Novartis leads the market with Pluvicto and Lutathera. Bayer, Telix Pharmaceuticals, and Lantheus are developing competing products. Major cancer centers including Memorial Sloan Kettering and MD Anderson have established dedicated theranostics programs.
Emerging Trends
Combination therapies pairing radiopharmaceuticals with immunotherapy and targeted agents are being explored. Alpha-emitter radiopharmaceuticals offering higher potency are in development. AI-powered dosimetry is optimizing treatment planning.
Future Outlook
Continued FDA approvals are expected to expand theranostics to additional cancer types, driving market growth through 2030.
Conclusion
FDA approvals are expanding clinical applications in the US theranostics market, transforming cancer care through precision medicine.
FAQ
Q1: What radiopharmaceuticals are FDA-approved for theranostics?
A: Pluvicto for prostate cancer and Lutathera for neuroendocrine tumors.
Q2: What new approvals are expected?
A: Agents for breast, lung, and colorectal cancers are in development.
#FDAApprovals #Theranostics #PrecisionOncology
Catégories
Lire la suite
Market Overview The pet arthritis market is expanding as owners of dogs, cats, and other companion animals seek broader joint care solutions beyond single-species treatment options. The market is projected to grow through the coming years, driven by rising pet longevity across species, growing veterinary diagnostic capability, and increased owner willingness to invest in chronic condition...
Ciabatta Market Conventional Products Lead Claim/Nature at 57.0% NEWARK, Del., September 25, 2026 According to Future Market Insights (FMI), the Ciabatta Market is projected to grow from USD 279.1 million in 2026 to USD 691.7 million by 2036, expanding at a 9.5% CAGR. Demand is being supported by foodservice sandwich menus, premium retail meals, and bakery formats that offer artisan texture,...
Market Overview The Medical Spa Market is being transformed by AI-driven skin diagnostics that map texture, pigmentation depth, and vascular patterns in under 60 seconds. Clinics are deploying these tools to visualize predicted outcomes, personalize treatment plans, and track longitudinal progress across multiple visits. The Medical Spa Market is projected to grow through 2035, propelled by...
The integration of artificial intelligence and digital workflow systems is rapidly reshaping clinical environments worldwide. Detailed analysis within the Dental Diagnostics And Surgical Equipment Market report highlights how advanced intraoral scanners, 3D cone-beam computed tomography (CBCT) systems, and laser-assisted surgical tools are enhancing procedural accuracy. These diagnostic...
Real-time PCR, also known as quantitative PCR, is a molecular biology technique that amplifies and quantifies DNA in real time. It is one of the most powerful tools in diagnostics, used to detect infections, genetic disorders, and cancer. In China, qPCR is central to clinical testing, research, and public health. As demand for rapid, accurate diagnostics grows, the qPCR market is expanding....